The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EORTC CLTF 2021 | Next steps in the development of CXCR4 inhibitors for mycosis fungoides
Lilach Moyal, PhD, Tel Aviv University, Tel Aviv, Israel, outlines the next steps in the development of CXCR4 inhibitors for the treatment of mycosis fungoides (MF). At the moment, research is focused on pre-clinical studies examining the mechanism of action of these agents and explore potential therapeutic candidates including plerixafor and other novel CXCR4 inhibitors. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
